This Article Full Text Full Text (PDF) All Versions of this Article: 40/8/2887    most recent STROKEAHA.109.552760v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Risselada, R. Articles by Sturkenboom, M. C.J.M. PubMed PubMed Citation Articles by Risselada, R. Articles by Sturkenboom, M. C.J.M. Related Collections Epidemiology Endothelium/vascular type/nitric oxide

(Stroke. 2009;40:2887.)
© 2009 American Heart Association, Inc.

Research Letters

Withdrawal of Statins and Risk of Subarachnoid Hemorrhage

Roelof Risselada, MD; Huub Straatman, MSc; Fop van Kooten, MD, PhD; Diederik W.J. Dippel, MD, PhD; Aad van der Lugt, MD, PhD; Wiro J. Niessen, PhD; Azadeh Firouzian, MSc; Ron M.C. Herings, PhD Miriam C.J.M. Sturkenboom, PharmD, PhD

From the Departments of Medical Informatics (R.R., W.J.N., A.F., M.C.J.M.S.), Neurology (F.v.K., D.W.J.D.), Radiology (A.v.d.L., W.J.N., A.F.), and Epidemiology (M.C.J.M.S.), and iBMG (R.M.C.H.), Erasmus MC, Rotterdam, the Netherlands; PHARMO Institute (H.S., R.M.C.H.), Utrecht, the Netherlands; and the Faculty of Applied Sciences (W.J.N.), Delft University of Technology, the Netherlands.

Correspondence to Roelof Risselada, MD, Department of Medical Informatics, Erasmus MC, room Ee 2159, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. E-mail r.risselada{at}erasmusmc.nl

Background and Purpose— Vascular endothelium, which can be affected by statins, is believed to play a substantial role in subarachnoid hemorrhage (SAH). Our objective was to estimate the association between use and withdrawal of statins and the risk of SAH.

Methods— We conducted a population-based case–control study within the PHARMO database. A case was defined as a person hospitalized for SAH (ICD-9-CM code 430) in the period January 1, 1998 to December 31, 2006. Ten randomly chosen controls were matched to each case on age, gender, and calendar date.

Results— During the study period 1004 incident cases of SAH were identified. Current use of statins did not significantly decrease the risk of SAH (OR=0.77, 95% CI 0.55 to 1.07). The odds ratio for recent withdrawal compared to nonusers was 1.62 (95% CI 0.96 to 2.73). Compared to current use, recent withdrawal was associated with an increased risk of SAH (OR=2.34, 95% CI 1.35 to 4.05). Interaction analysis showed that the effect of statin withdrawal was highest in patients who had also recently stopped antihypertensive drugs (OR=6.77, 95% CI 2.10 to 21.8).

Conclusions— Current use of statins seems to lower the risk of SAH, although the reduction was not significant in new users. Statin withdrawal increased the risk of SAH by a factor 2, even more in patients who had also recently stopped their antihypertensive treatment.

Key Words: subarachnoid hemorrhage • case–control study • 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors • statins • withdrawal